Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma
Status:
Completed
Trial end date:
2017-11-28
Target enrollment:
Participant gender:
Summary
The best way to combine a loco-regional procedure such as chemoembolisation or
radioembolization combined with an anti-angiogenic drug is not clear. This phase I trial aims
to establish, first, the tolerability of the combination of liver radioembolization with
SirSpheres® and sorafenib in uveal melanoma patients with liver metastasis studying different
schedules of administration of sorafenib after and before radioembolization. Secondly, we aim
to evaluate angiogenic markers modifications during these different schedules, either in the
serum or radiologicaly. Dose of Sorafenib will be 400 mg BID and the timing of introduction
will differ for one cohort to the other, given after the radioembolization for initials
cohorts and finally, before and concomitantly to radioembolization for the last cohort.
Phase:
Phase 1
Details
Lead Sponsor:
Centre Hospitalier Universitaire Vaudois Prof. Serge Leyvraz